Gracell Biotechnologies Inc. (NASDAQ:GRCL) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET
Company Participants
Dr. Kevin Xie - CFO
Dr. William Cao - Founder and CEO
Dr. Wendy Li - Chief Medical Officer
Conference Call Participants
Joe Catanzaro - Piper Sandler
Justin Zelin - BTIG
Kelly Shi - Jefferies
James Shin - Wells Fargo
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Gracell Biotechnologies Second Quarter 2022 Conference Call. At this time, all participants are in listen-only mode. After opening remarks, we will open the call for your questions. Instructions for queuing up will be given at that time.
I will now turn the conference call over to Dr. Kevin Xie, CFO. Please go ahead.
Dr. Kevin Xie
Good morning, and welcome to Gracell's second quarter 2022 corporate update conference call and webcast. With me today are Gracell's Founder and the Chief Executive Officer, Dr. William Cao; and our Chief Medical Officer, Dr. Wendy Li.
We're excited to discuss our innovative technologies and a rich clinical pipeline of CAR-T therapies on today's call. We're also looking forward to sharing with you our recent business developments and upcoming objectives for 2022. After our formal remarks, we'll conduct a question-and-answer session.
This morning, Gracell issued a press release announcing unaudited financial results for the quarter ended June 30, 2022. We encourage everyone to read this press release. And I would like to remind you that this call is being recorded for replay.
Please note that for certain information discussed on the call today, including financial data, clinical data and future plans of our programs, resource management will be making forward-looking statements. Actual results could differ materially from those stated or implied by those forward-looking statements as a result of various important factors. And please refer to the Risk Factors section of our latest 20-F filings with SEC for a full disclosure of these risks and factors.
The conference call contains time sensitive information that is accurate only as of the date of this live broadcast, August 15, 2022. Gracell undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by security laws.
I will now turn the call over to Gracell's CEO, Dr. William Cao. William?
Dr. William Cao
Welcome, everyone, to our second quarter 2022 corporate update conference call. I'm excited to begin today's call by highlighting our strengthened leadership team and then introducing our new CMO, Dr. Wendy Li, to the first investor call as part of the Gracell leadership team. I will ask her to provide some background and perspective on her recent move. I will then continue with a clinical development update as we made significant progress across a handful of our programs in recent months. Then I will hand the call over to our CFO, Dr. Kevin Xie, to discuss the financial updates. After our prepared remarks, we will open the call to the questions.